COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1

被引：1
|
作者：
Mernagh, P. [1 ]
Feng, J. [1 ]
Del Cuore, M. [2 ]
机构：
[1] Optum, Sydney, NSW, Australia
[2] Merck Sharp & Dohme Australia, Sydney, NSW, Australia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.440
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A94 / A94
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF TREATING CHRONIC HEPATITIS C GENOTYPE-1 WITH LEDIPASVIR AND SOFOSBUVIR IN GERMANY
    Stahmeyer, J. T.
    Rossol, S.
    Bert, F.
    Guerra, I. M.
    Krauth, C.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S642 - S643
  • [42] The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis
    Jacobs, RJ
    Koff, RS
    Meyerhoff, AS
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (02) : 427 - 434
  • [43] Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
    Moradpour, Darius
    Muellhaupt, Beat
    SWISS MEDICAL WEEKLY, 2012, 142
  • [44] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    de la Revilla, J.
    Crespo, J.
    Salcedo de Diego, I.
    Payares, C.
    Forns, X.
    Calleja, J. L.
    Avendano-Sola, C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E154 - E154
  • [45] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C - Reply
    Myers, RP
    Gregor, JC
    Marotta, PJ
    HEPATOLOGY, 2000, 32 (04) : 874 - 875
  • [46] Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection
    Zhou, Hui-Jun
    Wu, Gang
    Li, Ji-Ming
    Naidoo, Nasheen
    Xie, Yan-Xiang
    Feng, Bo-Lan
    Wang, Pei
    Luo, Ji-Wei
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (10) : 10313 - 10326
  • [47] EFFECTIVENESS AND COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR AND BOCEPREVIR FOR CHRONIC HEPATITIS C: A DECISION ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Borba, H. H.
    Rochau, U.
    Wiens, A.
    Sroczynski, G.
    Siebert, U.
    Pontarolo, R.
    VALUE IN HEALTH, 2017, 20 (09) : A883 - A883
  • [48] Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis
    Mar, Javier
    Mar-Barrutia, Lorea
    Gimeno-Ballester, Vicente
    San Miguel, Ramon
    MEDICINA CLINICA, 2016, 146 (02): : 61 - 64
  • [49] Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options
    Cortesi, P. A.
    Ciaccio, A.
    Rota, M.
    Lim, J. K.
    De Salvia, S.
    Okolicsanyi, S.
    Vinci, M.
    Belli, L. S.
    Mantovani, L. G.
    Strazzabosco, M.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (02) : 175 - 183
  • [50] The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4
    Kamal, S. M.
    Kassim, S.
    EL Gohary, E.
    Fouad, A.
    Nabegh, L.
    Hafez, T.
    Bahnasy, K.
    Hassan, H.
    Ghoraba, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 307 - 318
12345